Sonntag, 23. Oktober 2016

  • Pressemitteilung BoxID 44274

454 Sequencing Used at Institute of Genomics & Integrative Biology (IGIB) in India

(lifePR) (Penzberg, ) Roche has successfully installed the first Genome Sequencer FLX System at the prestigious IGIB, in Delhi, India. IGIB plans to use the system for all applications possible within this revolutionary technology, with a special focus on metagenomics and de novo genome sequencing. The Centre for Genomic Application (TCGA) will provide the sequencing services to the customers.

“The launch of the Genome Sequencer FLX System brings in the area of high throughput sequencing in India. We are confident that it will strengthen India’s place at the cutting edge of technology” – said Dr. Bhuwnesh Agrawal, the Managing Director of Indian affiliate of Roche Diagnostics and RAS champion of Asia Pacific.

IGIB, a premier Institute under CSIR (Council of Scientific & Industrial Research) was created with a mission to translate concepts developed in basic biological research to commercially viable technologies for health care. Towards this goal IGIB has been actively carrying out research leading to generation of new knowledge and development of technologies in various areas of Biotechnology with a special focus on Genomics and Genome Informatics.

The Centre for Genomic Application (TCGA) is a collaboration between the Institute of Genomics and Integrative Biology (IGIB), supported by Department of Science and Technology (DST) and Institute of Molecular Medicine (IMM-The Chatterjee Group). TCGA is the first ever public private partnership project providing life science services in India. It was established, with the best of technologies, to cut down the research time and cost, which is necessary if India had to be a global player in life sciences research, under the new patent regime. TCGA undertakes projects from design to data analysis and also offers highly flexible service packages that are tailored to meet customer needs.
454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative Genome Sequencer™ system for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of 454 Sequencing™ are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired reads. 454 Sequencing technology has enabled many peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology, and many more.
For additional information, please visit For more information on the technology, visit

1 Tauch A et al.: Ultrafast pyrosequencing of Corynebacterium kroppenstedtii DSM44385 revealed insights into the physiology of a lipophilic corynebacterium that lacks mycolic acids. J Biotechnol 2008 Mar 20 [Epub ahead of print]
2 Paviour S et al: Corynebacterium species isolated from patients with mastitis. Clin Infect Dis 2002; 35: 1434-1440
Diese Pressemitteilung posten:

Weitere Pressemitteilungen dieses Herausgebers